Says phase III trials showed 'no unexpected safety findings'. Armed with new phase III data, GlaxoSmithKline (GSK) has said it is on course to file for approval of its rheumatoid arthritis candidate sirukumab in 2016. Sirukumab is an interleukin-6 (IL-6) inhibitor, and one of a crop of new drugs that GSK has said could add at least Â£6bn to its revenues in 2020. The drug has been partnered with Johnson & Johnson's Janssen Biologics unit since 2011.
Agencies covered by the FAC-P/PM program may require additional training and experience beyond the basic FAC-P/PM requirements. Additional training is training in support of the agencyâs mission or the requirements of a program and project managerâs specific position.
Students must complete a minimum of six (6) courses to fulfill the public health minor requirements. This is achieved by taking four (4) required courses (Introduction to Public Health, a course in International Health, a course in Epidemiology, and a course in Statistics).